H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

The mean of analysts' price targets for Sarepta Therapeutics (SRPT) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...

H.C. Wainwright has recently initiated Sarepta Therapeutics Inc (SRPT) stock to Sell rating, as announced on November 25, 2024, according to Finviz. Earlier, on November 7, 2024, Cantor Fitzgerald had ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short ...

Per the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical ...